Climb Bio, Inc. 8-K

What Happened

• Climb Bio, Inc. (CLYM) filed an 8-K (Item 7.01) disclosing a virtual investor event held May 5, 2026 beginning at 8:00 a.m. ET. The event focused on budoprutug, the company’s clinical‑stage anti‑CD19 monoclonal antibody in development for primary membranous nephropathy, immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE). Copies of the related press release and presentation were furnished as exhibits.

Key Details

• Event date/time: May 5, 2026, starting at 8:00 a.m. ET.
• Drug and indications: budoprutug — anti‑CD19 mAb being developed for primary membranous nephropathy, ITP and SLE.
• Filing items: Item 7.01 (Regulation FD disclosure); related materials attached as Exhibits 99.1 (press release) and 99.2 (presentation).
• A live webcast and replay are available under the “News & Events” section of climbbio.com (company notes website content is not part of the filing).

Why It Matters

• The event provides investors with direct clinical and program updates on budoprutug, which could affect the company’s development timeline and perceived value of the asset. No financial results or executive changes were reported in this filing; it is a disclosure of investor communications under Regulation FD. Investors should watch for subsequent filings or press releases for trial data, regulatory milestones, or material business updates.